Screener
MBX Biosciences, Inc. MBX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total assets | $452,701 | $385,144 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $6,974 | $2,977 |
| Accrued expenses | 7,415 | 12,346 |
| Operating lease liability, current | 178 | 172 |
| Total current liabilities | 14,567 | 15,495 |
| Share repurchase liability | 1 | 2 |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s accounts payable?
- MBX Biosciences, Inc. (MBX) reported accounts payable of $6.97M in Q1 2026.
- How has MBX Biosciences, Inc.'s accounts payable changed year-over-year?
- MBX Biosciences, Inc.'s accounts payable increased by 64.3% year-over-year, from $4.25M to $6.97M.
- What is the long-term trend for MBX Biosciences, Inc.'s accounts payable?
- Over 2 years (2023 to 2025), MBX Biosciences, Inc.'s accounts payable has grown at a 213.9% compound annual growth rate (CAGR), from $1.7M to $16.75M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.
Ask your AI about MBX Biosciences, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude